CyclopamineCat. No. 1623 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: (2'R,3S,3'R,3'aS,6'S,6aS,6bS,7'aR,11aS,11bR)-1,2,3,3'a,4,4',5',6,6',6a,6b,7,7',7'a,8,11,11a,11b-Octadecahydro-3',6',10,11b-tetramethylspiro[9H-benzo[a]fluorene-9,2'(3'H)-furo[3,2-b]pyridin]-3-ol |
Biological Activity
Inhibitor of hedgehog (Hh) signaling, likely via direct inhibition of Smoothened, the accessory protein to the putative Hh receptor Patched. Anti-cancer and teratogenic in vivo. Depletes stem-like cancer cells in glioblastoma and blocks tumor engraftment. Can also be used to induce differentiation of human embryonic stem cells (hESCs) into hormone-expressing endocrine cells.Certificate of Analysis / Safety Data Sheet
References
Chen et al (2002) Inhibition of hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev. 16 2743. PMID: 12414725.
Scott (2003) Cancer: a twist in a hedgehog's tale. Nature 425 780. PMID: 14574396.
D'Amour et al (2006) Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat.Biotechnol. 24 1392. PMID: 17053790.
Bar et al (2007) Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25 2524. PMID: 17628016.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Cyclopamine, supplier, inhibitors, hedgehog, Hh, signaling, Signalling, Hedgehog, stem, cells, Smo, smoothened, antagonist
Quick Order
Find multiple products by catalog number
New Products in this Area
GPR35 agonist; more potent than zaprinast (Cat. No. 0947)
H2L 5765834LPA1,3,5 antagonist
CYM 50308Potent and selective S1P4 agonist
H2L5186303Potent and selective LPA2 receptor antagonist
MEDICA 16FFA1 (GPR40) agonist. Also inhibits ATP citrate lyase
BX 471Potent, selective CCR1 antagonist
PF 04418948Potent and selective EP2 receptor antagonist
LatanoprostFP prostaglandin receptor agonist; also exhibits agonist activity at EP1 and EP3 receptors
GRI 977143Selective LPA2 receptor non-lipid agonist
CYM 50260Potent and selective S1P4 agonist
G-36Selective GPR30 antagonist
Strontium chlorideCalcium sensing receptor (CaSR) agonist
CS 2100Selective S1P1 agonist
SMANT hydrochlorideInhibits Smoothened (Smo) accumulation
TUG 891Potent and selective GPR120 agonist
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.



